Unknown

Dataset Information

0

AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

ABSTRACT: Phosphoinositide-3-kinase (PI3K)-? inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance, we have observed that SCC cells that become refractory to PI3K? inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors from both laboratory models and patients treated with the PI3K? inhibitor BYL719. AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase C? (PLC?)-protein kinase C (PKC), which, in turn, activates mTOR. Combined treatment with PI3K? and either EGFR, AXL, or PKC inhibitors reverts this resistance.

SUBMITTER: Elkabets M 

PROVIDER: S-EPMC4398915 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance, we have observed that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors fr  ...[more]

Similar Datasets

Transcriptomics AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
2015-04-12 | E-GEOD-61515 | biostudies-arrayexpress
Transcriptomics AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
2015-04-12 | GSE61515 | GEO
Unknown EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
| S-EPMC3399735 | biostudies-literature
Unknown Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
| S-EPMC5950501 | biostudies-literature
Unknown Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.
| S-EPMC5045433 | biostudies-literature
Unknown Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review.
| S-EPMC7956931 | biostudies-literature
Unknown The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
| S-EPMC4056056 | biostudies-literature
Unknown Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
| S-EPMC4870591 | biostudies-literature
Unknown PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications.
| S-EPMC10215516 | biostudies-literature
Unknown Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
| S-EPMC7953989 | biostudies-literature